BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giri B, Belanger K, Seamon M, Bradley E, Purohit S, Chong R, Morgan JC, Baban B, Wakade C. Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A. Int J Mol Sci 2019;20:E4559. [PMID: 31540057 DOI: 10.3390/ijms20184559] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Kip E, Parr-Brownlie LC. Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson's disease. Ageing Res Rev 2022;78:101618. [PMID: 35395416 DOI: 10.1016/j.arr.2022.101618] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dong N, Dong Z, Chen Y, Gu X. Crocetin Alleviates Inflammation in MPTP-Induced Parkinson's Disease Models through Improving Mitochondrial Functions. Parkinsons Dis 2020;2020:9864370. [PMID: 33101635 DOI: 10.1155/2020/9864370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Rai SN, Singh P, Steinbusch HWM, Vamanu E, Ashraf G, Singh MP. The Role of Vitamins in Neurodegenerative Disease: An Update. Biomedicines 2021;9:1284. [PMID: 34680401 DOI: 10.3390/biomedicines9101284] [Reference Citation Analysis]
4 Khazdair MR, Kianmehr M, Anaeigoudari A. Effects of Medicinal Plants and Flavonoids on Parkinson's Disease: A Review on Basic and Clinical Evidences. Adv Pharm Bull 2021;11:224-32. [PMID: 33880344 DOI: 10.34172/apb.2021.026] [Reference Citation Analysis]
5 Moutinho M, Puntambekar SS, Tsai AP, Coronel I, Lin PB, Casali BT, Martinez P, Oblak AL, Lasagna-Reeves CA, Lamb BT, Landreth GE. The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease. Sci Transl Med 2022;14:eabl7634. [PMID: 35320002 DOI: 10.1126/scitranslmed.abl7634] [Reference Citation Analysis]
6 Söderbom G. Status and future directions of clinical trials in Parkinson's disease. Int Rev Neurobiol 2020;154:153-88. [PMID: 32739003 DOI: 10.1016/bs.irn.2020.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wakade C, Chong R, Seamon M, Purohit S, Giri B, Morgan JC. Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson's Disease: A Single-Center, Randomized, Placebo-Controlled Trial. Biomedicines 2021;9:1881. [PMID: 34944695 DOI: 10.3390/biomedicines9121881] [Reference Citation Analysis]
8 Doroftei B, Ilie OD, Cojocariu RO, Ciobica A, Maftei R, Grab D, Anton E, McKenna J, Dhunna N, Simionescu G. Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects. Molecules 2020;25:E3323. [PMID: 32707945 DOI: 10.3390/molecules25153323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chong R, Wakade C, Seamon M, Giri B, Morgan J, Purohit S. Niacin Enhancement for Parkinson's Disease: An Effectiveness Trial. Front Aging Neurosci 2021;13:667032. [PMID: 34220485 DOI: 10.3389/fnagi.2021.667032] [Reference Citation Analysis]
10 Bjørklund G, Dadar M, Anderson G, Chirumbolo S, Maes M. Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review. Pharmacol Res 2020;161:105065. [PMID: 32652199 DOI: 10.1016/j.phrs.2020.105065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Zhang H, Wang Z, Hu K, Liu H. Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson's disease model by targeting the miR-425-5p/TRAF5/NF-κB axis. J Biochem Mol Toxicol 2021;:e22867. [PMID: 34369042 DOI: 10.1002/jbt.22867] [Reference Citation Analysis]
12 Wallin J, Svenningsson P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease. Int J Mol Sci 2021;22:5606. [PMID: 34070609 DOI: 10.3390/ijms22115606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Scatozza F, Moschella F, D'Arcangelo D, Rossi S, Tabolacci C, Giampietri C, Proietti E, Facchiano F, Facchiano A. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res 2020;39:211. [PMID: 33028392 DOI: 10.1186/s13046-020-01719-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Grotemeyer A, McFleder RL, Wu J, Wischhusen J, Ip CW. Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification. Front Immunol 2022;13:878771. [PMID: 35663989 DOI: 10.3389/fimmu.2022.878771] [Reference Citation Analysis]
15 Munn C, Burton S, Dickerson S, Bakshy K, Strouse A, Rajesh D. Generation of cryopreserved macrophages from normal and genetically engineered human pluripotent stem cells for disease modelling. PLoS One 2021;16:e0250107. [PMID: 33886609 DOI: 10.1371/journal.pone.0250107] [Reference Citation Analysis]
16 Pérez MJ, Baden P, Deleidi M. Progresses in both basic research and clinical trials of NAD+ in Parkinson's disease. Mech Ageing Dev 2021;197:111499. [PMID: 33989633 DOI: 10.1016/j.mad.2021.111499] [Reference Citation Analysis]
17 Guo W, Liu J, Li W, Ma H, Gong Q, Kan X, Cao Y, Wang J, Fu S. Niacin Alleviates Dairy Cow Mastitis by Regulating the GPR109A/AMPK/NRF2 Signaling Pathway. Int J Mol Sci 2020;21:E3321. [PMID: 32397071 DOI: 10.3390/ijms21093321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rai SN, Singh P, Varshney R, Chaturvedi VK, Vamanu E, Singh MP, Singh BK. Promising drug targets and associated therapeutic interventions in Parkinson's disease. Neural Regen Res 2021;16:1730-9. [PMID: 33510062 DOI: 10.4103/1673-5374.306066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Karunaratne TB, Okereke C, Seamon M, Purohit S, Wakade C, Sharma A. Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease. Nutrients 2020;13:E28. [PMID: 33374784 DOI: 10.3390/nu13010028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]